Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

Logo poskytovatele

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

KUBICZKOVÁ Lenka KRYUKOV Fedor SLABÝ Ondřej KRYUKOVA Elena Vladimirovna JARKOVSKÝ Jiří NEKVINDOVÁ Jana RADOVÁ Lenka GREŠLIKOVÁ Henrieta KUGLÍK Petr VETEŠNÍKOVÁ Eva POUR Luděk ADAM Zdeněk ŠEVČÍKOVÁ Sabina HÁJEK Roman

Rok publikování 2014
Druh Článek v odborném periodiku
Časopis / Zdroj Haematologica/the hematology journal
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.3324/haematol.2013.093500
Obor Onkologie a hematologie
Klíčová slova Multiple myeloma; MGUS; circulating miRNA; miRNA profiling; qPCR
Popis Multiple myeloma still remains incurable in majority of cases prompting further search for new and better prognostic markers. Emerging evidence has suggested that circulating microRNAs can serve as minimally invasive biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. In this study, a global analysis of serum microRNAs by TaqMan Low Density arrays was performed, followed by quantitative real-time PCR. The analyses revealed five deregulated microRNAs: miR-744, miR-130a, miR-34a, let-7d and let-7e in monoclonal gammopathy of undetermined significance, newly diagnosed and relapsed multiple myeloma when compared to healthy donors. Multivariate logistic regression analysis showed that combination of miR-34a and let-7e can distinguish multiple myeloma from healthy donors with sensitivity 80.6% and specificity 86.7% and monoclonal gammopathy of undetermined significance from healthy donors with sensitivity 91.1% and specificity 96.7%. Furthermore, lower levels of miR-744 and let-7e were associated with shorter overall survival and remission of myeloma patients. One-year mortality rate for miR-744 and let-7e was 41.9% and 34.6% for ’low’ expression and 3.3% and 3.9% for ’high’ expression group, respectively. Median time of remission for both miR- 744 and let-7e was ~11 months for ’low’ expression and ~47 months for ’high’ expression groups of myeloma patients These data demonstrate that expression patterns of circulating microRNAs are altered in multiple myeloma and monoclonal gammopathy of undetermined significance and miR-744 with let-7e are associated with survival of myeloma patients.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info